emka MEDICAL is a technology company that develops monitoring systems for healthcare applications. We focus on invasive hemodynamic monitoring with the first application for heart failure management.

Heart failure (HF) is a common cardiovascular disease where the heart is not able to pump sufficiently to maintain normal blood flow. Globally there are roughly 38 million heart failure patients, in Germany alone there are around 1.6 million. HF contributes to around 1 to 2 % of overall healthcare costs. The big part of the costs are due to high readmission rates of HF patients. After a hospital admission, 25% of HF patients are readmitted after 30 days.

There is a major unmet medical need to reduce HF hospitalizations. Our disruptive hemodynamic monitoring technology aims to solve this problem. The CorLog product family will enable wireless mobile patient monitoring and early stage detection of changes in the health status of the HF patient.

Our first milestone on this path is to develop a short term right heart pressure monitoring probe which is called CorLog Probe 1P and can be used up to 30. The development of CorLog Probe 1P is co-funded by the Bavarian Ministry of Economic Affairs and Media, Energy and Technology.